Mereo BioPharma (MREO) Gross Profit (2023 - 2025)

Mereo BioPharma (MREO) posted quarterly Gross Profit of $400000.0 for Q2 2025, down 68.58% on a QoQ basis from $1.3 million in Q4 2023.

Mereo BioPharma (MREO) Gross Profit (2023 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported Gross Profit for 2 consecutive years, with $400000.0 the latest figure, recorded in Q2 2025.

Quarterly Gross Profit changed N/A year-over-year to $400000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $400000.0 (changed N/A YoY) and the FY2025 annual result came in at $367000.0, changed N/A from the prior year.
Gross Profit eased to $400000.0 in Q2 2025 per MREO's latest filing, from $1.3 million in the prior quarter.
Over the last five years, Gross Profit for MREO reached as high as $5.6 million in Q2 2023 and fell as low as -$347000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Mereo BioPharma	232.52 Mn	232.52 Mn	-

Download Data